Combination of Primary Hemostatic Disorders and Atrial Fibrillation Increases Bleeding Events Following Transcatheter Aortic Valve Replacement

Author:

Matsushita Kensuke12ORCID,Marchandot Benjamin1,Kibler Marion1,Carmona Adrien1,Phi Truong Dinh1,Heger Joe1,Trimaille Antonin1,Hess Sébastien1,Sattler Laurent3,Ohana Mickael4,Reydel Antje1,Jesel Laurence12,Ohlmann Patrick1,Morel Olivier12

Affiliation:

1. Université de Strasbourg, Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Strasbourg, France

2. UMR1260 INSERM, Nanomédecine Régénérative, Université de Strasbourg, Strasbourg, France

3. Department of Haemostasis, Centre Hospitalier Universitaire, Strasbourg, France

4. Department of Radiology, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Strasbourg, France

Abstract

Abstract Background Patients with atrial fibrillation (AF) are likely to have a poor prognosis including bleedings following transcatheter aortic valve replacement (TAVR). Closure time of adenosine diphosphate (CT-ADP) is a primary hemostasis point-of-care test and is a predictor of bleeding events following TAVR. We aimed to evaluate the impact of ongoing primary hemostatic disorders on bleeding events in TAVR patients with AF. Methods We enrolled 878 patients from our prospective registry. The primary endpoint was VARC-2 major/life-threatening bleeding complications (MLBCs) at 1 year after TAVR and secondary endpoint was major adverse cardiac and cerebrovascular events (MACCEs) at 1 year, defined as a composite of all-cause death, myocardial infarction, stroke, and heart failure hospitalization. Ongoing primary hemostatic disorder was defined by a postprocedural CT-ADP >180 seconds. Results Patients with AF had a higher incidence of MLBCs (20 vs. 12%, p = 0.002), MACCE (29 vs. 20%, p = 0.002), and all-cause mortality (15 vs. 8%, p = 0.002) within 1 year compared to non-AF patients. When the cohort was split into four subgroups according to AF and CT-ADP >180 seconds, patients with AF and CT-ADP >180 seconds had the highest risk of MLBCs and MACCE. Multivariate Cox regression analysis confirmed that the patients with AF and CT-ADP >180 seconds had 3.9-fold higher risk of MLBCs, whereas those patients were no longer associated with MACCE after the adjustment. Conclusion In TAVR patients, AF with postprocedural CT-ADP >180 seconds was strongly associated with MLBCs following TAVR. Our study suggests that persistent primary hemostatic disorders contribute to a higher risk of bleeding events particularly in AF patients.

Funder

Edwards Lifesciences

GERCA

Publisher

Georg Thieme Verlag KG

Subject

General Medicine

Reference32 articles.

1. Durability of transcatheter and surgical bioprosthetic aortic valves in patients at lower surgical risk;L Søndergaard;J Am Coll Cardiol,2019

2. Transcatheter versus surgical aortic-valve replacement in high-risk patients;C R Smith;N Engl J Med,2011

3. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers notion randomized clinical trial;H G Thyregod;J Am Coll Cardiol,2015

4. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients;M J Mack;N Engl J Med,2019

5. Bleeding complications drive in-hospital mortality of patients with atrial fibrillation after transcatheter aortic valve replacement;A Lother;Thromb Haemost,2020

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Extensive Impairment of the Hemostatic System Increases Bleeding Events;JACC: Cardiovascular Interventions;2023-12

2. Reply;JACC: Cardiovascular Interventions;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3